Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kanda, Atsuhiro ^a   Noda, Kousuke ^a   Saito, Wataru ^a   Ishida, Susumu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENIC FACTOR; GALECTIN 1; HYBRID PROTEIN; MESSENGER RNA; PROTEIN BINDING; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANTAGONISTS AND INHIBITORS; CELL LINE; DIABETIC RETINOPATHY; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN ANALYSIS; RETINAL PIGMENT EPITHELIUM;

ANGIOGENESIS INDUCING AGENTS; CELL LINE; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; GALECTIN 1; GENE EXPRESSION REGULATION; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84949575372     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17946     Document Type: Article

References (45)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186 (1971).
2. Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027 (2005).
3. Hoeben, A. et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56, 549-580 (2004).
4. Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118, 445-450 (1994).
5. Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 16, 1107-1111 (2010).
6. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355, 1419-1431 (2006).
7. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342 (2004).
8. Ng, E. W. et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5, 123-132 (2006).
9. Do, D. V. et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118, 1819-1826 (2011).
10. Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537-2548 (2012).
11. Tabernero, J. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50, 320-331 (2014).
12. Ikuno, Y. et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology 122, 1220-1227 (2015).
13. Ogura, Y. et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3. GALILEO study. Am J Ophthalmol 158, 1032-1038 (2014).
14. Brown, D. M. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155, 429-437 e427 (2013).
15. Campochiaro, P. A. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122, 538-544 (2015).
16. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99, 11393-11398 (2002).
17. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171-185 (2012).
18. Croci, D. O. et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744-758 (2014).
19. Alge, C. S. et al. Galectin-1 influences migration of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 47, 415-426 (2006).
20. Uehara, F., Ohba, N. & Ozawa, M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci 42, 2164-2172 (2001).
21. Zhao, X. Y. et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis 31, 1367-1375 (2010).
22. Kondo, T. & Kahn, C. R. Altered insulin signaling in retinal tissue in diabetic states. J Biol Chem 279, 37997-38006 (2004).
23. Lin, M. et al. Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization. Invest Ophthalmol Vis Sci 53, 6197-6206 (2012).
24. Poulaki, V. et al. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J 21, 2113-2123 (2007).
25. D'Haene, N. et al. VEGFR1 and VEGFR2 involvement in extracellular galectin-1-and galectin-3-induced angiogenesis. PLoS One 8, e67029 (2013).
26. Marth, J. D. & Grewal, P. K. Mammalian glycosylation in immunity. Nat Rev Immunol 8, 874-887 (2008).
27. Ohtsubo, K. & Marth, J. D. Glycosylation in cellular mechanisms of health and disease. Cell 126, 855-867 (2006).
28. Astorgues-Xerri, L. et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40, 307-319 (2014).
29. Pugliese, G. et al. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 49, 1249-1257 (2000).
30. Thijssen, V. L. et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103, 15975-15980 (2006).
31. Toscano, M. A. et al. Nuclear factor (NF)-kappaB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol 48, 1940-1949 (2011).
32. Thijssen, V. L., Poirier, F., Baum, L. G. & Griffioen, A. W. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110, 2819-2827 (2007).
33. Mathieu, V. et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127, 2399-2410 (2007).
34. Inafuku, S. et al. Alteration of N-Glycan Profiles in Diabetic Retinopathy. Invest Ophthalmol Vis Sci 56, 5316-5322 (2015).
35. Lux, A., Llacer, H., Heussen, F. M. & Joussen, A. M. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91, 1318-1322 (2007).
36. Otsuji, T. et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol 7, 1487-1490 (2013).
37. Chang, A. A. et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 121, 188-192 (2014).
38. Batioglu, F., Demirel, S., Ozmert, E., Abdullayev, A. & Bilici, S. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmol 15, 40 (2015).
39. Kumar, N. et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33, 1605-1612 (2013).
40. Diabetic Retinopathy Clinical Research, N. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372, 1193-1203 (2015).
41. Ando, R. et al. Aqueous humour levels of placental growth factor in diabetic retinopathy. Acta Ophthalmol 92, e245-246 (2014).
42. Hosoya, K. et al. Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. Exp Eye Res 72, 163-172 (2001).
43. Satofuka, S. et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetesinduced retinal inflammation. Diabetes 58, 1625-1633 (2009).
44. Kanda, A., Noda, K., Oike, Y. & Ishida, S. Angiopoietin-like protein 2 mediates endotoxin-induced acute inflammation in the eye. Lab Invest 92, 1553-1563 (2012).
45. Dong, Z. et al. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Mol Vis 19, 536-543 (2013).